Xenix Medical Announces FDA Clearance and Full Commercial Launch of the Lux™ Expandable Lumbar Interbody Fusion System
Expandable Design Incorporates the Company’s NanoACTIV™ Surface and NeoWave™ Structure Technologies to Enhance the Potential for Fusion While Minimizing the Risk of Subsidence
Xenix Medical today announced FDA 510(k) clearance and full commercial launch for its Lux Expandable Lumbar Interbody Fusion System.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608333749/en/ GIF Animation of the Lux Expandable Interbody Fusion Device
Lux is the result of strong market demand for an expandable interbody fusion device that does not compromise the potential for fusion. Whereas traditional expandable devices incorporate bulky expansion mechanisms that occupy space typically reserved for bone graft material, Lux allows for significant post-expansion bone graft packing and features the company’s NanoACTIV surface technology to support postoperative bone growth throughout the device. NanoACTIV, an FDA-designated nanotechnology, comprises proprietary macro-, micro-, and nanoscale features that have been shown in vitro to elicit mesenchymal stem cell differentiation through the osteogenic lineage.
